List of Artificial Intelligence Companies in Pennsylvania - 22

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use. The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

Geisinger Medical Laboratories, a medical reference laboratory in Pennslyvania (PA). Dedicated to caring, laboratory excellence, patient safety, quality assurance, and service excellence.

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

Patient populations and their medications are continuously moving. MedTek21 ensures your entire patient base is continuously monitored for potential drug/gene interaction risks, allowing you to focus your care.

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

Ocean Genomics works with biopharma, academic researchers and advocacy to empower discovery and development. We provide our advanced computing platforms for gene expression analysis, and biomarker and target discovery, and our vast and fast-growing gene expression database. We also provide integrated programs ranging from single experiment analyses to multi-milestone efforts that include computational biologists, and use of all of our platforms, AI models and data assets.

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg cells all the way to newborn screening, our innovative platform technology can provide more efficient and affordable fertility treatment strategies. We are looking for investors, distribution and implementation partners. Join us for making fertility journey affordable and efficient.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

Proscia is a software company accelerating pathology's transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and AI-powered computational pathology software are redefining the pathology laboratory and enhancing cancer diagnosis.

Imagine a world where genetic diseases are treated with orally-available small molecule drugs. That's the future Sharp Edge Labs is building. Sharp Edge is a preclinical-stage life sciences company developing drugs for genetic diseases. Our monogenic disease focus de-risks the clinical path. Each pipeline program has a genetically identifiable subset of patients and an early Phase IB pharmacodynamic readout. We combine three core techologies to create a scalable platform for discovery and development. CoreX(tm) is s suite of assay technologies that enable the creation of realistic cellular models of genetic diseases. AlloChem(tm) is a proprietary compound library computationally biased to contain molecules that can bind proteins allosterically, stabilizing them, and restoring their function. Disco/Mine(tm) is a suite of computational and machine learning tools that enhances our experimental approach rather than replacing it. These combine to create a scalable platform with over 10 programs at various stages of development. The company has programs in Frontotemporal Dementia, and genetic subsets of Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders and other loss-of-function diseases. The team and its advisors includes ex and current Genzyme/Sanofi, Synageva, Pfizer and Shire executives.

We believe that fingerprinting the immune system can be a game-changer when it comes to improving the surgical journey for millions of patients. Combining innovative technologies with artificial intelligence, our multidisciplinary team of clinicians, engineers and scientists is focused on holistically improving the standard-of-care. Predicting the risk for complications before surgery is critical to allow personalization of pre-operative clinical interventions, surgical decision-making and improvement of surgical outcomes. 30% of major surgeries result in complications within 30 days postoperatively, such as infection or pneumonia, and even death. Surge is grounded in more than seven years of clinical, basic science, and translational research led by our team at Stanford University. Our test combines single-cell assessment of the immune system before surgery with clinical data available through Electronic Health Records (EHR) using a proprietary machine learning algorithm. Individual immune systems are comprehensively assessed from a single blood sample obtained before surgery and analyzed using mass cytometry. Our method allows us to mimic surgical trauma in a test tube with a small amount of blood containing millions of immune cells before surgery. We use this technique to understand exactly how every immune cell in your body is responding to the trauma to precisely predict postoperative outcomes.

The InfantEar Molding System can easily be performed in your medical office and requires only 2-3 weeks of molding time to transform a deformed ear into a healthy and more natural-looking ear, if treated in the first two weeks of life. Contact TalexMedical, LLC

ThirdLaw Molecular LLC has pioneered the development of Spiroligomer™ molecules and is developing this innovative, patent-protected, therapeutic modality into a new class of more targeted medicines. The mission of the Company is to create a revolutionary category of molecules that transform how diseases are diagnosed and treated – more safely and effectively.

Traws Pharma is a clinical stage company aiming to address unmet medical needs in respiratory viral diseases and cancer. We leverage broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations.

🧬🤖🖥 Vivodyne accelerates the discovery of cures to human diseases with highly scalable drug testing on lab-grown 3D human tissues.